RedHill Biopharma (RDHL) Return on Sales (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Return on Sales data on file, last reported at 0.33% in Q2 2023.

• On a quarterly basis, Return on Sales rose 32.0% year-over-year to 0.33% in Q2 2023; TTM through Jun 2023 was 0.01%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.27%, up 28.0% from the prior year.
• Return on Sales for Q2 2023 stood at 0.33%, up from 0.02% in the prior quarter.
• Over the last five years, Return on Sales for RDHL reached as high as 0.33% in Q2 2023 and fell as low as 0.06% in Q4 2021.
• Historically, Return on Sales has averaged 0.04% across 5 years, with a median of 0.01% in 2021.
• Across the five-year window, Return on Sales fell 15 bps in 2021 and soared 32 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.07% in 2019, then sank by 86 bps to 0.01% in 2020, then tumbled by 697 bps to 0.06% in 2021, then grew by 10 bps to 0.05% in 2022, then jumped by 704 bps to 0.33% in 2023.
• Per Business Quant data, the three most recent Return on Sales figures were 0.33% in Q2 2023, 0.02% in Q1 2023, and 0.05% in Q4 2022.